Teva Reports Results of Austedo (deutetrabenazine) in Two Clinical Studies for Tourette Syndrome

 Teva Reports Results of Austedo (deutetrabenazine) in Two Clinical Studies for Tourette Syndrome

Teva Reports Results of Austedo (deutetrabenazine) in Two Clinical Studies for Tourette Syndrome

Shots:

  • The P-II/III ARTISTS 1 & P-III ARTISTS 2 studies involve assessing of Austedo vs PBO in 119 & 158 pediatric patients (6-16 yrs.) in a ratio (1:1) & (1:1:1) over 12 & 8wks. dosing for the treatment of tics in patients with mod. to severe TS
  • The P-II/III ARTISTS 1 & P-III ARTISTS 2 studies resulted in not meeting its 1EPs i.e. reduction in motor and phonic tics as assessed by YGTSS-TTS. The studies were conducted in collaboration with Teva and Nuvelution Pharma
  • Austedo is a VMAT2 inhibitor and has received the US FDA’s approval for the treatment of chorea associated with Huntington’s disease in Apr’2017 and for tardive dyskinesia in Aug’2017

Click here to­ read full press release/ article | Ref: Businesswire | Image: Teva

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post